Rapidly progressive interstitial lung disease (RP-ILD) in patients with clinically amyopathic dermatomyositis (CADM) associated with antibodies to melanoma differentiation-associated gene5 (MDA5) results in a high mortality rate. We experienced a case of anti-MDA5-positive RP-ILD of CADM which showed a response to rituximab, although there was no significant effect due to standard immunosuppressive treatment. This case suggests that rituximab has the potential to offer an effective agent for the treatment of anti-MDA5-positive RP-ILD of CADM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/14397595.2015.1014140 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful tocilizumab treatment for rapidly progressive interstitial lung disease with anti-MDA5-positive juvenile dermatomyositis: a case report and literature review.
Front Pediatr
November 2024
Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Background: Currently, no established integrated treatment regimen exists for anti-melanoma differentiation-associated gene 5 (anti-MDA5)-positive juvenile dermatomyositis (JDM) complicated by rapidly progressive interstitial lung disease (RP-ILD). We present a case of refractory anti-MDA5-positive JDM with RP-ILD that was successfully treated using a combination of tocilizumab and plasma exchange, along with a review of the relevant literature.
Methods: A literature review was conducted to gain insights into the clinical features and treatment strategies for managing refractory anti-MDA5-positive JDM complicated by RP-ILD.
Refractory skin ulcers and afebrile bacteremia with Staphylococcus aureus in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a case report.
Mod Rheumatol Case Rep
December 2024
Department of Rheumatology, Tohoku University Hospital, Sendai, Japan.
The skin ulcers sometimes appear in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM), and usually associates with disease activity. Here, we report a case of 41-year-old woman with anti-MDA5 antibody-positive DM, who developed refractory skin ulcers during the remission induction therapy, which were proven to be associated with clinically silent Staphylococcus aureus bacteremia with septic thrombi in her lung. The patient was referred to our hospital for the treatment of amyopathic DM with interstitial lung disease.
View Article and Find Full Text PDFCritical Crossroads: The Vital Role of Timely Diagnosis in Severe Amyopathic Dermatomyositis.
Cureus
October 2024
Internal Medicine Department, Hospital Prof. Dr. Fernando Fonseca, Lisbon, PRT.
Clinically amyopathic dermatomyositis (CADM) is an uncommon subtype of dermatomyositis (DM) characterized by the typical cutaneous manifestations of DM but without clinical or enzymatic signs of muscle inflammation. We report a case of a 61-year-old woman with a four-week history of dry cough, myalgias, chills, pleuritic chest pain, and worsening shortness of breath. She also had a five-year history of inflammatory polyarthralgia.
View Article and Find Full Text PDFClinicopathological features and treatment outcome of juvenile idiopathic inflammatory myopathies with anti-melanoma differentiation associated gene 5 antibodies: A case series study.
Medicine (Baltimore)
August 2024
Department of Neurology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
To characterize the clinicopathological features and treatment outcomes of juvenile idiopathic inflammatory myopathies (JIIM) with anti-melanoma differentiation associated gene 5 (MDA5) antibodies in a Chinese cohort. Anti-MDA5 antibody was detected by immunodot assay and indirect immunofluorescence assay on HEK293 cells in a series of Chinese JIIM cohort between 2005 and 2022. The clinical features, histological findings, and treatment outcomes of these anti-MDA5-antibody-positive patients were summarized.
View Article and Find Full Text PDFA case of refractory anti-MDA5-positive amyopathic dermatomyositis successfully treated with upadacitinib.
J Dermatolog Treat
December 2024
Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Amyopathic dermatomyositis (ADM) is a rare, idiopathic, connective tissue disease and melanoma differentiation-associated protein 5 (MDA5) antibody-positive ADM is more treatment-resistant, especially in patients with interstitial lung disease (ILD). The purpose of this article is to report a case of anti-MDA5-positive ADM successfully treated with JAK inhibitor Upadacitinib. A 35-year-old Chinese woman presented with recurrent itchy erythema on her face and scalp for 4 years.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!